血浆可溶性二肽基肽酶-4与非心源性急性缺血性卒中后认知障碍
基于CATIS试验的预计划辅助研究纳入600例非心源性缺血性卒中患者,随访3个月用蒙特利尔认知评估评价认知功能。血浆sDPP4最高四分位较低最低四分位者认知障碍风险降低,调整OR为0.49(95%CI 0.29-0.81;趋势P=0.011),对数转换sDPP4每增加1个标准差风险降低17%(OR 0.83,95%CI 0.70-0.99)。
要点
- 血浆sDPP4最高四分位较低最低四分位者卒中后认知障碍调整OR为0.49(95%CI 0.29-0.81;趋势P=0.011)。
- 对数转换血浆sDPP4每增加1个标准差,认知障碍风险降低17%(OR 0.83,95%CI 0.70-0.99)。
- 将血浆sDPP4加入基础模型后,无类别净重分类改善为19.10%(95%CI 2.52%-35.68%;P=0.03)。
核心结论
- 较高的血浆sDPP4水平与非心源性缺血性卒中后认知障碍风险降低相关。
研究设计与样本
- 基于CATIS试验的预计划辅助研究,纳入600例非心源性缺血性卒中患者。
- 缺血性卒中后3个月随访时用蒙特利尔认知评估评价认知功能,用二元逻辑回归分析血浆sDPP4与后续认知障碍的关联。
主要发现
- 血浆sDPP4最高四分位较低最低四分位者卒中后认知障碍调整OR为0.49(95%CI 0.29-0.81;趋势P=0.011)。
- 对数转换血浆sDPP4每增加1个标准差,卒中后认知障碍风险降低17%(OR 0.83,95%CI 0.70-0.99)。
- 将血浆sDPP4加入含常规危险因素的基础模型后,无类别净重分类改善为19.10%(95%CI 2.52%-35.68%;P=0.03),综合判别改善为0.79%(95%CI 0.13%-1.46%;P=0.02)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: DPP4 (dipeptidyl peptidase-4) inhibitors have been proven to promote neuronal regeneration, reverse the development of cognitive deficits. However, the association of circulating soluble form (sDPP4 [soluble DPP4]) with poststroke cognitive impairment (PSCI) is unclear. We aimed to investigate the association between plasma sDPP4 levels and PSCI in patients with ischemic stroke. METHODS: A total of 600 noncardioembolic stroke patients were included based on a preplanned ancillary study from the CATIS (China Antihypertensive Trial in Acute Ischemic Stroke). We used the Montreal Cognitive Assessment to evaluate cognitive function at 3 months follow-up after ischemic stroke. Binary logistic regression analyses were performed to investigate the association of plasma sDPP4 levels with subsequent PSCI. We further calculated integrated discrimination improvement and category-free net reclassification improvement to investigate the incremental prognostic effect of plasma sDPP4 beyond the basic model with conventional risk factors. RESULTS: Plasma sDPP4 was inversely associated with PSCI after ischemic stroke, and the adjusted odds ratio (95% CI) for the highest versus lowest quartile of sDPP4 was 0.49 (0.29-0.81; P for trend=0.011). Each 1-SD increase of logarithm-transformed plasma sDPP4 concentration was associated with 17% (odds ratio, 0.83 [95% CI, 0.70-0.99]) lower risk of PSCI. Adding plasma sDPP4 to the basic model notably improved risk reclassification for PSCI, as shown by a category-free net reclassification improvement of 19.10% (95% CI, 2.52%-35.68%; P=0.03) and integrated discrimination improvement of 0.79% (95% CI, 0.13%-1.46%; P=0.02). CONCLUSIONS: Higher plasma sDPP4 levels were associated with decreased risk of cognitive impairment after noncardioembolic ischemic stroke.
引用
- You S, Bi Y, Miao M, et al. Plasma sDPP4 (Soluble Dipeptidyl Peptidase-4) and Cognitive Impairment After Noncardioembolic Acute Ischemic Stroke. Stroke. 2022. PMID: 36475470. doi:10.1161/STROKEAHA.122.040798
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。